All the studies I've ever found indicate most people are happy with premium lenses. Data collected in studies is a more reliable thing to look at than the anecdotal impression gotten by a doctor, even a good doctor. Unfortunately some doctors don't like dealing with any complaints, and therefore any issues may seem like "many" to them, they prefer the conservative "safe" approach. Its actually a good marketing strategy since if they are the "safe" doctor then they get patients referred there, and don't have problem patients scaring people off. That doesn't mean that their conservative approach is the best one for everyone.
Those with monofocal lenses may not express unhappiness the way a minority of those with premium lenses do, however they may not be as happy with their vision as they might have been with premium lenses. Most people are happy with whatever option they receive. Many folks are willing to have some risk of problems in exchange for a better result for the rest of their lives, but some doctors don't like seeing any problems and talk patients out of it. A problem patient scares off other prospective patients.
re: "doesn't believe MF manufacturers are here to stay or there would be a lot more companies investing in the technology"
That isn't a credible argument, I see a decent amount of activity in the sector and its not clear what sort of evidence and reasoning he could provide as to why it "should" or would be more. Doctors don't necessarly know much about business or the world of tech investing (I've been an entrepreneur, and networking with other entrepreneurs, in the software&net tech and startup world for decades, though not the medical device world).
There are many premium lenses available outside the US that aren't approved in the US, and the companies don't even bother trying to get them approved due to the high costs involved. Even the US company behind the Symfony didn't try for approval here until after it was approved elsewhere, and its likely if they didn't already have a big distribution network in the US they wouldn't have bothered. I haven't heard anything yet about US company Alcon trying for approval for the Panoptix trifocal it now has approved in Europe. The US in general tends to do a disproportionately large share of medical R&D, in addition to having one of the larger potential markets for premium lenses, so the problems with the US market likely reduces the R&D budget quite a bit. The FDA's problems likely have far more to do with the level of investment in new IOLs than anything to do with the technology itself.
There isn't infinite funding available for all the potential R&D projects that might lead to something useful in every potential niche in the world. Companies compete for R&D funding, including competing with other industries looking for investment. They need to factor in things like risk and the total budget required to get something to market. There is a huge cost to get a new medical device developed and approved, and risk that while all that is being spent a competitor might beat them to the punch, or some unforseen problem might arise.
Premium lenses currently have a fairly low market share, mostly due to not being covered by insurers or government payment programs, and partly since some doctors are cautious and there isn't yet a lens without some risks. Some think the lower risk profile of the Symfony might lead it to boost the market share of premium lenses, but its hard to say. Regardless the current limited market size limits the amount of R&D funding, even though people realize that in theory a "perfect" (or at least "near-perfect"
IOL might have a huge payday by expanding the share of premium IOLs greatly. That near- perfect IOL doesn't exist, and any investment in a candidate path to get there has technical risk that it might not achieve its goals (or might not be approved) or risk it might have a limited time on the market before a better competitor arises, etc. Its not a sure thing that investors will necessarily pour money into, depending on whatever competing investment options there are.